Quintela-Fandino, MiguelSoberon, NoraLluch, AnaManso, LuisCalvo, IsabelCortes, JavierMoreno-Antón, FernandoGil-Gil, MiguelMartinez-Jánez, NoeliaGonzalez-Martin, AntonioAdrover, Encarnade Andres, RaquelViñas, GemmaLlombart-Cussac, AntonioAlba, EmilioMouron, SilvanaGuerra, JuanBermejo, BegoñaZamora, EstherGarcía-Saenz, Jose AngelSimon, Sonia PernasCarrasco, EvaEscudero, María JoséCampo, RuthColomer, RamónBlasco, Maria A2025-01-072025-01-072017https://hdl.handle.net/10668/25129Cumulative toxicity from weekly paclitaxel (myalgia, peripheral neuropathy, fatigue) compromises long-term administration. Preclinical data suggest that the burden of critically short telomeres ( 21.9% CSTs) had 2-fold higher number of neuropathy (P = 0.04) or fatigue (P = 0.019) episodes and >3-fold higher number of myalgia episodes (P = 0.005). The average telomere length was unrelated to the incidence of side effects.The percentage of CSTs, but not the average telomere size, is associated with weekly paclitaxel-derived toxicity.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/breast cancercritically short telomerestelomere lengthtoxicityweekly paclitaxelAdultAgedAged, 80 and overAntineoplastic AgentsBreast NeoplasmsChemotherapy, AdjuvantFemaleHumansIn Situ Hybridization, FluorescenceIndolesMiddle AgedNeoadjuvant TherapyPaclitaxelTelomereTelomere Shorteningresearch article28423524open access10.18632/oncotarget.155921949-2553PMC5400599http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=15592&path%5B%5D=49804https://pmc.ncbi.nlm.nih.gov/articles/PMC5400599/pdf